Back to search results

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

Abroad (travel likely)RecruitingPHASE1

Conditions

Relapsed or Refractory Acute Myeloid Leukemia (AML) · Untreated AML · Other IDH1-mutated Positive Hematologic Malignancies · Myelodysplastic Syndromes

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • University of Alabama at Birmingham, Birmingham, Alabama, United States

  • Mayo Clinic-AZ, Phoenix, Arizona, United States

  • City of Hope, Duarte, California, United States

  • University of California-Los Angeles, Los Angeles, California, United States

  • University of California-San Francisco, San Francisco, California, United States

  • University of Colorado Denver, Aurora, Colorado, United States

  • Mayo Clinic-Jacksonville, Jacksonville, Florida, United States

  • University of Miami, Miami, Florida, United States

  • Moffit Cancer Center, Tampa, Florida, United States

  • Emory University, Atlanta, Georgia, United States

  • Northwestern University Medical Hospital, Chicago, Illinois, United States

  • John Hopkins Cancer Center, Baltimore, Maryland, United States

  • Massachusetts General Hospital, Boston, Massachusetts, United States

  • Dana Farber Cancer Institute, Boston, Massachusetts, United States

  • Karmanos Cancer Center, Detroit, Michigan, United States

  • Washington University, St Louis, Missouri, United States

  • Memorial Sloan Kettering Cancer Center, New York, New York, United States

  • Cornell Cancer Center, New York, New York, United States

  • Duke Cancer Center, Durham, North Carolina, United States

  • Cleveland Clinic, Cleveland, Ohio, United States

  • Ohio State University, Columbus, Ohio, United States

  • Oregon Health and Science University, Portland, Oregon, United States

  • Medical University of South Carolina, Charleston, South Carolina, United States

  • Sarah Cannon Research Institute, Nashville, Tennessee, United States

  • UT Southwestern Medical Center, Dallas, Texas, United States

  • MD Anderson Cancer Center, Houston, Texas, United States

  • Hopital La Timone, Marseille, France

  • Hopital Haut-Leveque, Pessac, France

  • Central Lyon Sud, Pierre-Bénite, France

  • Institute Gustave Roussly (IGR), Villejuif, France

View source on ClinicalTrials.gov(opens in a new tab)